Psoriatic Arthritis Market Summary

• The approved therapies in the Psoriatic Arthritis Therapeutics Market include upadacitinib (RINVOQ; AbbVie), Deucravacitinib (SOTYKTU; Bristol Myers Squibb), Bimekizumab (BIMZELX; UBC), Risankizumab (SKYRIZI; AbbVie), Guselkumab (TREMFYA; Johnson & Johnson), and others.
• The Psoriatic Arthritis Companies include Sun Pharmaceutical Industries (Tildrakizumab [ILUMYA]), Affibody Medical (Izokibep), Johnson & Johnson (Icotrokinra [JNJ-77242113] and JNJ-88545223), Takeda Pharmaceuticals (Zasocitinib [TAK-279]), AltruBio (ALTB-168), Merck Sharp & Dohme (Tulisokibart [MK-7240-015]), and others.

Psoriatic Arthritis Market & Epidemiology Analysis

• Psoriatic Arthritis is generally a progressive condition, with a substantial proportion of patients developing structural joint damage over time if inadequately treated, despite advances in biologic therapy.
• As per National Psoriasis Foundation, roughly 1 in 3 people living with psoriasis also have Psoriatic Arthritis.
• Majority of patients fall under mild-to-moderate disease (~70–85%), while ~15–25% progress to severe disease.
• The disease typically affects adults aged 30–50 years, with a near equal male-to-female distribution, although males more frequently present with axial disease and females often report higher pain burden and functional impairment.
• Treatment paradigm is shifting from TNF Inhibitors to IL-17, IL-23, Tyrosine kinase 2 Inhibitors, and oral targeted therapies.
• Risankizumab has emerged as a leading therapy in the Psoriatic Arthritis Market, supported by strong efficacy across joint and skin domains, durable response rates, and a favorable long-term safety profile, driving widespread physician adoption.
• Novel biologic candidates such as izokibep and other IL-17 pathway agents are being developed to enhance tissue penetration, improve response rates, and address refractory patient populations.
• Biosimilar entry in older TNF inhibitor classes is intensifying pricing pressure and accelerating switching toward newer IL-17 and IL-23 agents, reshaping competitive dynamics.
• Despite significant therapeutic advances, a substantial proportion of patients with Psoriatic Arthritis continue to experience incomplete response, persistent pain, fatigue, and progression across disease domains, highlighting the need for true disease modification, predictive biomarkers, and more durable long-term treatment strategies.

Request for Unlocking the Sample Page of the Report @ "Psoriatic Arthritis Treatment Market"

Psoriatic Arthritis Market Size and Forecast in the 7MM

Key Factors Driving the Psoriatic Arthritis Market Growth

• Rising Disease Prevalence and Better Diagnosis

Psoriatic Arthritis diagnosis is increasing due to better screening in psoriasis patients and improved imaging techniques. Earlier detection expands the treated patient pool, especially in developed markets. This directly increases long-term therapy demand.

• Shift Toward Biologics & Targeted Therapies

IL-17, IL-23, and JAK inhibitors are replacing conventional disease-modifying antirheumatic drugs (DMARDs) due to higher efficacy and better disease control. These agents improve both joint and skin outcomes, making them first-line options in many cases. This is the main revenue driver of the market.

• Strong Innovation Pipeline

New mechanisms like TYK2 inhibitors and oral IL-23 pathway blockers are expanding treatment choices. Companies are focusing on differentiated, next-generation immunology assets. This increases competition and market expansion.

DelveInsight's ‘Psoriatic Arthritis Market Insights, Epidemiology and Market Forecast – 2036’ report delivers an in-depth understanding of the Psoriatic Arthritis, historical and forecasted epidemiology, as well as the Psoriatic Arthritis market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Psoriatic Arthritis Treatment Market Report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates Psoriatic Arthritis patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022–2036) across global regions. The report highlights key unmet medical needs in Psoriatic Arthritis and maps the competitive and clinical landscape to uncover high‑value opportunities, providing a clear outlook on future market growth potential.

Psoriatic Arthritis Understanding and Treatment Algorithm

Psoriatic Arthritis Overview and Diagnosis

Psoriatic Arthritis is a chronic immune-mediated inflammatory disease that affects both the skin and joints and is strongly associated with psoriasis. It is characterized by joint pain, swelling, stiffness, enthesitis (inflammation at tendon/ligament insertion sites), and dactylitis (sausage digits). The disease follows a heterogeneous course, ranging from mild peripheral arthritis to severe erosive joint damage and axial involvement.

Early diagnosis is critical because irreversible structural damage can occur if treatment is delayed. Diagnosis of Psoriatic Arthritis is primarily clinical, supported by classification criteria such as the CASPAR (Classification Criteria for Psoriatic Arthritis), which includes evidence of psoriasis, nail changes, negative rheumatoid factor, dactylitis, and radiographic findings. Imaging techniques like X-ray, ultrasound, and MRI help detect joint inflammation, erosions, and enthesitis at an early stage.

Laboratory tests are mainly used to exclude other conditions like rheumatoid arthritis, as there is no single definitive biomarker for Psoriatic Arthritis.

Current Psoriatic Arthritis Treatment Landscape

Psoriatic Arthritis treatment is aimed at achieving disease remission or low disease activity while preventing irreversible joint damage and improving quality of life. Management typically follows a stepwise approach, starting with Nonsteroidal Anti-Inflammatory Drug (NSAIDs) and conventional DMARDs such as methotrexate in mild disease, and progressing to biologics in moderate-to-severe cases.

Key biologic classes include TNF inhibitors, IL-17 inhibitors, and IL-23 inhibitors, while oral targeted therapies like JAK and TYK2 inhibitors are increasingly important due to their convenience and efficacy. Therapy selection is individualized based on dominant symptoms, comorbidities, and patient response patterns.

Psoriatic Arthritis Unmet Needs

The section “unmet needs of Psoriatic Arthritis” outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Safety limitations of long-term therapy
2. Patients do not achieve sufficient response to current biologics or targeted therapies
3. Lack of predictive biomarkers for personalized therapy
4. High economic burden and restricted access, and others…..

Note: Comprehensive unmet needs insights in Psoriatic Arthritis and their strategic implications are provided in the full report.

Psoriatic Arthritis Epidemiology

Key Findings from Psoriatic Arthritis Epidemiological Analysis and Forecast

• Globally, Psoriatic Arthritis Prevalence at approximately 0.1–0.2%.
• Approximately 2.4 million individuals in the United States are living with Psoriatic Arthritis, representing the prevalent patient population burden of the disease.
• More than 15% of people living with psoriasis may also have undiagnosed Psoriatic Arthritis in the United States.
• The average age of onset of Psoriatic Arthritis is 30–50 years.
• Among patients with psoriasis, approximately 20% develop Psoriatic Arthritis, although this proportion varies according to age, disease severity, classification criteria, and region.

Psoriatic Arthritis Epidemiology Segmentation

• Total Psoriatic Arthritis Prevalent Cases
• Total Psoriatic Arthritis Diagnosed Prevalent Cases
• Psoriatic Arthritis Diagnosed Prevalent Cases by Gender
• Psoriatic Arthritis Diagnosed Prevalent Cases by Age
• Psoriatic Arthritis Diagnosed Prevalent Cases by Severity
• Psoriatic Arthritis Treated Cases

Psoriatic Arthritis Market Recent Breakthroughs and Developments

• In May 2026, Affibody announced that positive 52-week data from a global Phase IIb/III study of izokibep in Psoriatic Arthritis was presented as an oral presentation at the European Congress of Rheumatology (EULAR) 2026. Izokibep met the primary endpoint of ACR50 at 16 weeks with high statistical significance.
• In March 2026, Sun Pharmaceutical announced that the US FDA had accepted for review the supplemental Biologics License Application (sBLA) for tildrakizumab for the treatment of adults with active Psoriatic Arthritis. The FDA regulatory action date for this sBLA is expected by October, 2026.

Psoriatic Arthritis Drug Analysis & Competitive Landscape

The Psoriatic Arthritis drug chapter provides a detailed, market-focused review of the emerging Psoriatic Arthritis Pipeline across Phase II-III clinical trials and preclinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments.

This section offers critical insights into the Psoriatic Arthritis treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the Psoriatic Arthritis therapeutics market.

Psoriatic Arthritis Approved Therapies

• Deucravacitinib (SOTYKTU): Bristol Myers Squibb

Deucravacitinib is the first TYK2 inhibitor to be approved for Psoriatic Arthritis. Bristol Myers Squibb on March 2026, announced that the US FDA had approved deucravacitinib for the treatment of adults with active Psoriatic Arthritis. The approval is based on positive results from the pivotal POETYK PsA-1 and POETYK PsA-2 trials, which evaluated the efficacy and safety of deucravacitinib in adults with active Psoriatic Arthritis.

In both trials, treatment with deucravacitinib resulted in significant improvement in disease activity, as measured by American College of Rheumatology (ACR) 20 (the primary endpoint) and Minimal Disease Activity (MDA) response (key secondary endpoint).

• Bimekizumab (BIMZELX): UBC

Bimekizumab is the first approved treatment for Psoriatic Arthritis that is designed to selectively inhibit two key cytokines driving inflammatory processes, interleukin 17A (IL-17A) and interleukin 17F (IL-17F). This newly approved indications follow the first US approval for BIMZELX in October 2023 for the treatment of moderate-to-severe plaque psoriasis. As per UBC’s annual report 2025, BIMZELX’s net sales in 2025 was USD 2.5 billion.

Note: Detailed marketed therapies assessment will be provided in the final report.

Psoriatic Arthritis Pipeline Analysis

• Tildrakizumab (ILUMYA): Sun Pharmaceutical Industries 

It is a humanized monoclonal antibody targeting the IL-23 p19 subunit, currently approved for moderate-to-severe plaque psoriasis and under clinical evaluation for Psoriatic Arthritis. Ongoing trials are assessing its efficacy in improving joint symptoms, enthesitis, dactylitis, and skin manifestations. Its selective IL-23 inhibition may provide durable disease control with a favorable safety profile, potentially expanding its role in the Psoriatic Arthritis Treatment landscape.

• Izokibep: Affibody Medical

It is an investigational IL-17A inhibitor based on Affibody technology, designed for high target affinity and enhanced tissue penetration. It is being evaluated in Phase III clinical trials for Psoriatic Arthritis, where early studies have shown promising improvements in joint and skin symptoms. If successful, izokibep could offer a differentiated treatment option for patients with inadequate responses to existing biologic therapies.

Note: Detailed emerging therapies assessment will be provided in the final report.

Psoriatic Arthritis Companies

• Bristol Myers Squibb
• UBC
• AbbVie
• Johnson & Johnson
• Sun Pharmaceutical Industries
• Affibody Medical
• Takeda Pharmaceuticals
• AltruBio
• Merck Sharp & Dohme, and others

Psoriatic Arthritis Market Outlook

The Psoriatic Arthritis treatment landscape has expanded significantly over the past decade with the introduction of biologic DMARDs and targeted synthetic DMARDs. While TNF inhibitors continue to represent an important therapeutic class, newer agents targeting the IL-17, IL-23, and TYK2 pathways are increasingly reshaping treatment algorithms due to their ability to address multiple disease domains, including peripheral arthritis, skin psoriasis, enthesitis, dactylitis, and axial involvement.

Among the approved therapies, Risankizumab is expected to strengthen its market position owing to its robust efficacy across both joint and skin manifestations, convenient maintenance dosing schedule, and expanding clinical evidence. Bimekizumab is also anticipated to gain significant market share because of its dual inhibition of IL-17A and IL-17F, offering rapid and durable responses in patients with active PsA.

Deucravacitinib, an oral TYK2 inhibitor originally approved for plaque psoriasis, has officially become a targeted oral treatment option for adult patients with active Psoriatic Arthritis following successful Phase III POETYK trials and subsequent global regulatory approvals.

The late-stage pipeline continues to diversify the competitive landscape. Tildrakizumab is being evaluated for Psoriatic Arthritis and may provide an additional IL-23-targeted option, although it is expected to face strong competition from established agents within the same class.

• Icotrokinra, an investigational oral peptide targeting the IL-23 receptor, has generated considerable interest due to its novel mechanism and potential to combine biologic-like efficacy with the convenience of oral administration.
• Izokibep, a high-affinity IL-17A inhibitor based on Affibody technology, has demonstrated promising efficacy in clinical studies and may differentiate itself through enhanced tissue penetration and rapid symptom improvement. If approved, both candidates could expand treatment options for patients with inadequate responses to existing biologics.

Key Findings from Psoriatic Arthritis Market Forecast Report

• The Psoriatic Arthritis Market across the 7MM is expected to experience steady growth through 2036, supported by increasing disease awareness, earlier diagnosis, and continued innovation in targeted immunology. The shift toward highly selective cytokine inhibitors and oral targeted therapies is expected to intensify competition while improving long-term patient outcomes.
• Risankizumab and bimekizumab are expected to remain among the fastest-growing biologic therapies due to their strong efficacy across multiple Psoriatic Arthritis domains.
• Deucravacitinib and icotrokinra could expand the oral treatment segment by offering targeted, convenient alternatives to injectable biologics.

Psoriatic Arthritis Drug Class/Insights into Leading Emerging and Marketed Therapies (2022–2036 Forecast)

The Psoriatic Arthritis Market (2022–2036 forecast) is increasingly shifting toward precision immunomodulatory therapies that selectively target cytokines and intracellular signaling pathways involved in disease pathogenesis.

• IL-23 Inhibitors: This class includes risankizumab and tildrakizumab, which selectively inhibit the p19 subunit of interleukin-23, thereby suppressing the IL-23/Th17 inflammatory pathway. These biologics have demonstrated durable efficacy in controlling both joint and skin manifestations.
• IL-17 Pathway Inhibitors: Bimekizumab is a dual IL-17A/IL-17F inhibitor, while izokibep is an investigational high-affinity IL-17A inhibitor based on Affibody technology. By directly inhibiting IL-17-mediated inflammation, these agents provide rapid improvements in musculoskeletal and dermatologic symptoms.
• TYK2 Inhibitors: Deucravacitinib is a selective oral TYK2 inhibitor that modulates cytokine signaling downstream of IL-23, IL-12, and type I interferons.

Overall, innovation in Psoriatic Arthritis is increasingly centered on selective cytokine inhibition and targeted oral immunotherapies. While IL-17 and IL-23 inhibitors currently dominate the biologic market, emerging oral TYK2 inhibitors and IL-23 receptor antagonists are expected to diversify treatment options, address unmet needs related to convenience and long-term disease control, and support sustained market growth across the 7MM through 2036.

Psoriatic Arthritis Drug Uptake

This section focuses on the uptake rate of potential Psoriatic Arthritis drugs expected to be launched in the market during the forecast period (2026–2036). The analysis covers the Psoriatic Arthritis drug’s uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

Among approved therapies, risankizumab and bimekizumab are expected to drive the majority of market growth in Psoriatic Arthritis due to strong efficacy across joint and skin symptoms and favorable dosing convenience. Risankizumab, already a multi-billion-dollar product across indications, is anticipated to maintain steady Psoriatic Arthritis uptake with expanding biologic penetration, supported by its durable response rates and quarterly maintenance dosing.

Bimekizumab is projected to record faster uptake growth owing to its dual IL-17A/IL-17F inhibition, which offers rapid symptom control and high skin clearance rates, positioning it as a strong competitor in the IL-17 class. Overall, marketed biologics are expected to remain the backbone of Psoriatic Arthritis treatment, with IL-23 and IL-17 inhibitors capturing an increasing share from older TNF inhibitors.

Among emerging candidates, tildrakizumab is expected to see limited Psoriatic Arthritis uptake despite its IL-23 mechanism, as it remains more established in plaque psoriasis and faces strong intra-class competition. Icotrokinra holds high disruptive potential due to its novel mechanism and convenience, with expected rapid adoption in early-line therapy if approved. Collectively, these emerging agents are expected to intensify competition, particularly in the oral and IL-17/IL-23 targeted segments, and gradually shift treatment preference toward more convenient and precision-driven therapies.

Detailed insights of emerging therapies' drug uptake is included in the report

Psoriatic Arthritis Market Access and Reimbursement of Approved Therapies

Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

The United States

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc. 

NOTE: Further Details are provided in the final report….

Psoriatic Arthritis Therapies Price Scenario & Trends 

Pricing and analogue assessment of Psoriatic Arthritis therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Psoriatic Arthritis Industry Experts and Physician Views

To keep up with Psoriatic Arthritis Therapeutics Market Trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the Psoriatic Arthritis emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in Psoriatic Arthritis, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 15+ KOLs to gather insights at the country level. Centers such as University of Rochester Medical Center, University of California San Diego, and Heinrich Heine University Düsseldorf, etc. were contacted. Their opinion helps understand and validate current and emerging Psoriatic Arthritis therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in Psoriatic Arthritis.

Psoriatic Arthritis Report Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and Psoriatic Arthritis Therapeutics Market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis. In the SWOT analysis of Psoriatic Arthritis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical Psoriatic Arthritis accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial’s primary and secondary outcome measures are evaluated, whereas the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are mainly observed.

In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided. 

Scope of the Psoriatic Arthritis Therapeutics Market Report

• The Psoriatic Arthritis Therapeutics Market Report covers a segment of key events, an executive summary, a descriptive overview, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along Psoriatic Arthritis Treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborate profiles of late-stage and prominent therapies, will have an impact on the current Psoriatic Arthritis Treatment landscape.
• A detailed review of the Psoriatic Arthritis market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Psoriatic Arthritis Therapeutics Market Report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Psoriatic Arthritis Drugs Market.

Psoriatic Arthritis Market Report Insights

• Psoriatic Arthritis Patient Population Forecast
• Psoriatic Arthritis Therapeutics Market Size
• Psoriatic Arthritis Pipeline Drugs Analysis
• Psoriatic Arthritis Market Size and Trends
• Psoriatic Arthritis Market Opportunity (Current and Forecasted)

Psoriatic Arthritis Market Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast
• Psoriatic Arthritis Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (By Geography)
• Psoriatic Arthritis Treatment Addressable Market (TAM)
• Psoriatic Arthritis Competitive Landscape
• Psoriatic Arthritis Major Companies Insights
• Psoriatic Arthritis Price Trends and Analogue Assessment
• Psoriatic Arthritis Therapies Drug Adoption/Uptake
• Psoriatic Arthritis Therapies Peak Patient Share Analysis

Psoriatic Arthritis Market Report Assessment

• Current Psoriatic Arthritis Treatment Practices
• Psoriatic Arthritis Unmet Needs
• Psoriatic Arthritis Clinical Development Analysis
• Psoriatic Arthritis Emerging Drugs Product Profiles
• Psoriatic Arthritis Market Attractiveness
• Psoriatic Arthritis Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions Answered in the Psoriatic Arthritis Treatment Market Report

Psoriatic Arthritis Therapeutics Market Insights

• What was the Psoriatic Arthritis Treatment Market Size, the Psoriatic Arthritis Market Size by therapies, Psoriatic Arthritis Drugs Market Share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of Psoriatic Arthritis?
• What are the disease risks, burdens, and unmet needs of Psoriatic Arthritis?
• What will be the growth opportunities across the 7MM concerning the patient population with Psoriatic Arthritis?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of Psoriatic Arthritis?
• What are the current guidelines for treating Psoriatic Arthritis in the US, Europe, and Japan?

Reasons to Buy the Psoriatic Arthritis Market Report

• The Psoriatic Arthritis Therapeutics Market Report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Psoriatic Arthritis Drugs Market.
• Bottom-up forecasting builds from the affected population to product forecasts, delivering a robust, data-driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease Psoriatic Arthritis Incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the Psoriatic Arthritis Drugs Market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Psoriatic Arthritis Drugs Market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI)-enabled report summarizes and simplifies complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data-driven decisions.

Stay updated with us for Recent Articles

• HUMIRA Biosimilars in the US: The Talk of the Psoriatic Arthritis Treatment Market
• Psoriatic Arthritis Market Infographics
• New DelveInsight Blogs